Chief Scientific Officer, Antabio

I obtained a PhD in Microbiology from the University of Bristol studying the molecular mechanisms of β-lactamase induction and pursued post-doctoral studies within the Antibiotic Research Group, University of Birmingham, on the mechanisms of fluoroquinolone resistance in clinical isolates. In 1996 I joined Glaxo Wellcome integrating anti-tubercular projects from academic collaborators into the internal discovery process. Within GSK, I joined the Molecular Screening department, running a high-throughput screening group and leading several antibacterial and anticancer discovery programs. In 2005 I joined MerLion Pharmaceuticals in Singapore becoming Head of Research, leading the internal research and natural products CRO business, before joining Antabio in late 2012, becoming CSO.